CXCL8 and cystic fibrosis: TMA (4,6,4′-trimethylangelicin) (Figure 1) is a small molecule known to modulate the function of CFTR and control the inflammatory status of CF by targeting NF-κB and reducing IL-8 expression, demonstrating to be a promising agent for the treatment of CF [7,8,9].